Search Results
Your search for where matches 5550 pages
Showing 2251 - 2300Residual Cancer Burden Is Prognostic of Outcomes Across Breast Cancer Subtypes
Residual cancer burden after neoadjuvant chemotherapy can accurately predict disease recurrence and survival across all breast cancer subtypes, according to the findings from a meta-analysis presented at the 2019 San Antonio Breast Cancer Symposium by W. Fraser Symmans, MD, Professor and Director...
Does Proton Pump Inhibitor Use Affect Cognition in Breast Cancer Survivors?
Proton pump inhibitors, which are sometimes recommended to ease stomach problems during cancer treatment, may have an unintended side effect: impairment of breast cancer survivors' memory and concentration. These findings were published by Madison et al in the Journal of Cancer Survivorship....
Mixed Results With Weekly Nab-paclitaxel, Denosumab in Primary Breast Cancer
A weekly schedule of nab-paclitaxel as part of neoadjuvant chemotherapy significantly improved pathologic complete response compared with nab-paclitaxel given 2 weeks out of every 3 weeks (2/3) in patients with primary breast cancer, with a greater magnitude of benefit in patients with...
Comparing Options for Ovarian Tissue Cryopreservation to Preserve Fertility in Pediatric Patients With Cancer
With the pediatric cancer survival rate exceeding 80%, “we can reasonably suspect that most of these children will survive more than 5 years from their diagnosis and then go on to puberty,” when they may have to deal with the consequences of cancer treatment, according to Rebecca Flyckt, MD,...
Are Women in Europe or Asia More Likely to Have Breast-Conserving Therapy Than Those in the United States?
Neoadjuvant systemic therapy can shrink tumors in patients with breast cancer and, in some cases, allow patients to receive breast-conserving therapy who would otherwise require mastectomy. However, in the United States, about 55% of patients who become eligible for breast-conserving therapy after...
Blinatumomab Outperforms Chemotherapy as Post-Reinduction Consolidation Therapy in Younger Patients With B-Cell ALL
Blinatumomab was superior to standard chemotherapy in children, adolescents, and young adults at the first relapse of B-cell acute lymphoblastic leukemia (ALL) as post-reinduction consolidation therapy prior to hematopoietic stem cell transplant (HSCT), according to the results of a late-breaking...
Use of Artificial Intelligence for Diagnosing and Grading Prostate Cancer
Researchers have developed a method based on artificial intelligence (AI) for the histopathologic diagnosis and grading of prostate cancer. The study, published by Ström et al in The Lancet Oncology, showed that the AI system can be trained to detect and grade prostate cancer from needle biopsy...
Transplantation Specialist Karen Ballen, MD, Treasures Long-Term Connections With Her Patients
Karen Ballen, MD, an international expert in stem cell transplantation, particularly for patients who have a difficult time finding a donor, was born and reared in the Bronx in a family that encouraged academic and professional pursuits. “My grandfather was an old-fashioned pediatrician who made...
Patient Access to High-Quality Oncologic Pathology Improves Care
Accurate and timely diagnoses are critical components for developing treatment plans for patients with cancer and also for informing prognosis and assessment of responses. Pathologists are an essential part of the oncology team because they have specialized knowledge that helps inform diagnostic...
Expert Point of View: Gary Schiller, MD
At the press conference where these data were presented, moderator Gary Schiller, MD, of the University of California, Los Angeles, explained that although chimeric antigen receptor (CAR) T-cell therapy is a major advance in cellular immunotherapy, enabling killing of cancer cells in blood and bone ...
FDA Finalizes Enforcement Policy on Unauthorized Flavored Cartridge-Based E-Cigarettes
Amid the epidemic levels of youth use of e-cigarettes and the popularity of certain products among children, the U.S. Food and Drug Administration (FDA) has issued a policy prioritizing enforcement against certain unauthorized flavored e-cigarette products that appeal to children, including fruit...
Highlights From the 2019 ASCO Research Community Forum Annual Meeting
Researchers from around the country joined together for learning and collaboration at the 2019 ASCO Research Community Forum (RCF) Annual Meeting in September. During the meeting, Aisha Peterson Johnson, MD, MPH, MBA, of the U.S. Food and Drug Administration (FDA) Office of Compliance, delivered a...
ASCO and IASLC Collaborate to Improve the Quality of Lung Cancer Care in Brazil
Medical oncologists in Brazil are being encouraged to take advantage of a new measure set for assessing the quality of care they provide to patients with lung cancer. Lung cancer is one of the most prevalent and deadly types of cancer in Brazil.1 Providing a platform for health-care providers to...
Oncology Analytics Appoints Lee Newcomer, MD, as Strategic Advisor
Oncology Analytics, a technology-enabled service company that provides health plans, providers, and patients with an evidence-based, analytics-focused approach to utilization management, purpose-built for oncology, has announced the appointment of Lee Newcomer, MD, as a strategic advisor. Dr....
Professor Jean-Charles Soria Appointed General Director of Gustave Roussy
In a statement from Gustave Roussy on December 16, 2019, the following news was released: “By an order, the Minister of Health and Solidarity, Madame Agnès Buzyn, appointed Professor Jean-Charles Soria as General Director of Gustave Roussy for a term of 5 years. He will assume his responsibilities...
Edmondo Robinson, MD, MBA, FACP, Joins Moffitt as Chief Digital Innovation Officer
Edmondo Robinson, MD, MBA, FACP, has joined Moffitt Cancer Center in Tampa as the new Senior Vice President and Chief Digital Innovation Officer. This newly created position will be critical to Moffitt’s success and navigating a continually evolving health-care industry. Dr. Robinson brings over...
My Dream Is That Multiple Myeloma Will One Day Be in My Past and No Longer a Part of My Future
A year before my diagnosis of multiple myeloma, in 2010, my husband Paul and I moved with our six children to Monterrey, Mexico, where Paul was helping to create a venture capital industry. We were so busy settling into a new country and getting our children integrated into school that when I...
FDA Pipeline: Priority Reviews in SCLC, Bladder Cancer, Colorectal Cancer
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Reviews for treatments in extensive-stage small cell lung cancer (SCLC), non–muscle invasive bladder cancer, and BRAF V600E–mutant colorectal cancer. The Agency also recently issued multiple Breakthrough Therapy designations and ...
Incidence of Squamous Cell Carcinoma of the Anus Has ‘Increased Dramatically’ in Older Women and Young Black Men
“Squamous cell carcinoma of the anus incidence has increased dramatically in elderly women and young black men,” according to a study of recent trends in incidence and mortality. “Advanced-stage [anal squamous cell carcinoma] incidence tripled with a prominent rise in … mortality,” researchers...
Coexisting With Cancer and Depression
Among the highlights at the 2019 Supportive Care in Oncology Symposium in October was the keynote address by Thomas J. Smith, MD, FACP, FASCO, FAAHPM, the Harry J. Duffey Family Professor of Palliative Medicine and Director of Palliative Medicine at Johns Hopkins Medicine and Professor of Oncology ...
Acupuncture May Reduce Radiation-Induced Dry Mouth for Patients With Head and Neck Cancer
After receiving acupuncture treatment 3 days a week during the course of radiation treatment, patients with head and neck cancer experienced less dry mouth, according to study results published by Garcia et al in JAMA Network Open. The results are from the first randomized, placebo-controlled,...
Relapsed or Refractory Multiple Myeloma Outcomes Improving Exponentially
Emerging treatments for relapsed or refractory multiple myeloma include options beyond triplet regimens, including immunotherapy and mutation-driven therapy. Several exciting drugs are poised to be available in the clinic in 2020, according to speakers at the recent JADPRO Live, the annual...
ASTRO Issues Clinical Guideline on Radiation Therapy for Basal Cell and Cutaneous Squamous Cell Carcinomas
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy to treat patients diagnosed with the most common types of skin cancers. The guideline details when radiation treatments are appropriate as stand-alone therapy...
A Systematic Approach to Identifying the Molecular Factors That Lead to Cancer Progression
Although gene mutations are the primary drivers of carcinogenesis, an array of complex and tumor-specific molecular interaction networks determine cancer cell behavior. To learn more about this line of inquiry, The ASCO Post recently spoke with Andrea Califano, Dr., Professor of Chemical Biology...
Lung Cancer Expert Julie R. Brahmer, MD, MSc, Was an Early Believer in Immunotherapy—and Still Is
Lung cancer specialist Julie R. Brahmer, MD, MSc, comes from a long line of Midwest farmers who still run a family operation. “I’m originally from what I would call the middle of nowhere in Nebraska. My father is a sixth-generation farmer, and my mother is a nurse. I was inclined toward medicine at ...
SABCS 2019: Oral vs Intravenous Paclitaxel for Patients With Metastatic Breast Cancer
Patients with metastatic breast cancer who received an oral formulation of paclitaxel had better response and survival and less neuropathy than patients who received intravenous paclitaxel, according to results of a phase III trial presented at by Umanzor et al at the San Antonio Breast Cancer...
Scott A. Gerber, PhD, Named Inaugural Kenneth E. and Carol L. Weg Distinguished Professor at Dartmouth
Scott A. Gerber, PhD, has been named the Kenneth E. and Carol L. Weg Distinguished Professor at Geisel School of Medicine at Dartmouth College. Dr. Gerber is the first to hold this newly established professorship. Dr. Gerber is Professor of Molecular and Systems Biology and of Biochemistry and...
NCCN Updates Genetic Screening Guidelines
The National Comprehensive Cancer Network® (NCCN®) recently announced publication of the newest genetic risk assessment recommendations for breast, ovarian, and pancreatic cancers. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment:...
Studies Show the U.S. Health-Care System Hampered by Waste and Trailing Other High-Income Countries
Recent studies show that at least one-quarter of our nation’s health-care expenditures are being consumed by waste, fraud, and abuse. Moreover, since 2004, annual reports from the Commonwealth Fund have consistently rated the performance of our health-care system last among high-income countries,...
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Earlier this month, the American Society of Hematology (ASH) published new state-of-the-art guidelines on the treatment of immune thrombocytopenia. The guidelines were published in the journal Blood Advances.1 The 2019 ASH Clinical Practice Guidelines on Immune Thrombocytopenia, developed in...
Working to Improve Survival Rates in Pancreatic Cancer
Although pancreatic cancer survival rates have slowly improved over the past few decades for all stages of pancreatic cancer combined, the 1-year rate is 20%, and the 5-year rate is about 9%. There is no single diagnostic test to detect pancreatic cancer, and less than 20% of tumors are confined to ...
An Early Interest in Biology and People Led to a Career in Oncology for Nina Shah, MD
Multiple myeloma expert Nina Shah, MD, was born and reared in the Northeast. During grade school, she developed a passion for science that would lead to an early decision to pursue a career in medicine. “My ninth-grade biology class really got me interested in human biology, and that’s when I...
Mary Jo Turk, PhD, Named O. Ross McIntyre, MD, Professor at Dartmouth College
Mary Jo Turk, PhD, has been named the O. Ross McIntyre, MD, Professor at the Geisel School of Medicine at Dartmouth College. Professor of Microbiology and Immunology and Co-Director of the Immunology and Cancer Immunotherapy Program at Dartmouth’s Norris Cotton Cancer Center, Dr. Turk joined the...
The Light at the End of the Tunnel in Urothelial Cancer Is Not a Train: Enfortumab Vedotin and Other Developments
There is an urgent need to develop new drugs for the treatment of urothelial cancer. Chemotherapy was the only approved treatment in advanced disease for 40 years, which was associated with response rates of between 30% and 50% in the front-line setting.1-3 However, durable remissions were...
For Your Patients: What Are Tumor Marker Tests for Cancer? Eight Things You Need to Know
Cancer.Net provides timely, comprehensive, oncologist-approved information for patients from ASCO with support from Conquer Cancer®, the ASCO Foundation. Cancer.Net brings the expertise and resources of ASCO to people living with cancer and those who care for them to help patients and families make ...
Erlotinib Plus Ramucirumab: Ready for Prime Time?
The treatment of epidermal growth factor receptor (EGFR)-positive lung cancer changed dramatically after the results of the FLAURA trial showed improved progression-free survival with the third-generation EGFR tyrosine kinase inhibitor osimertinib as first-line therapy compared with...
ASH 2019: PET-Directed Therapy for Early-Stage DLBCL
Most people diagnosed with early-stage, or limited, diffuse large B-cell lymphoma (DLBCL) may be able to safely skip radiation treatment after a clear positron-emission tomography (PET) scan, according to new clinical trial results from SWOG presented by Persky et al at the 2019 American Society of ...
Making Inroads With Interventional Oncology in the Treatment of Solid Tumors
At the recent 2019 Symposium on Clinical Interventional Oncology (CIO) in Miami, course directors Constantino Peña, MD, FSIR, and Ripal Gandhi, MD, FSIR, FSVM, had a lot to say about this burgeoning field of oncology. In particular, interventional oncology is making inroads in therapeutic...
Expert Point of View: Angela Lamarca, MD, PhD, Ian Chau, MD, and Per Pfeiffer, MD, PhD
Angela Lamarca, MD, PhD, of the Christie NHS Foundation Trust, Manchester, United Kingdom, served as European Society for Medical Oncology (ESMO) commentator for the ClarIDHy trial in a press briefing held during the ESMO Congress 2019. Dr. Lamarca acknowledged, “The reported median...
ClarIDHy and FIGHT-202 Trials Show Positive Results in the Treatment of Patients With Biliary Tract Cancer
Two studies reported at the European Society for Medical Oncology (ESMO) Congress 2019—ClarIDHy and FIGHT-202—demonstrated clinical benefits with novel molecularly targeted agents in the treatment of advanced cholangiocarcinoma. Currently, first-line treatment for locally advanced or metastatic...
Databases: Where Math Meets Medicine
About 4 decades ago, as a young physician, I observed that most surgeons were numerator doctors; they remembered their successes and their failures, but they did not remember the frequency of either. There was no denominator. Worse, the approach to any specific surgical problem was always the...
ASH 2019: Is Autologous Hematopoietic Stem Cell Transplant Safe and Effective for Patients Aged 70 or Older With Multiple Myeloma?
Even though autologous hematopoietic stem cell transplantation (AHCT) is an effective treatment for multiple myeloma, only 4 out of 10 patients receive this therapy. A new study presented by Munshi et al at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 782) ...
ASH 2019: Phase Ib/II Study of BCMA-Directed CAR T-Cell Therapy for Pretreated Multiple Myeloma
Patients with multiple myeloma who had received a median of five prior therapies with refractory disease had a high response rate when treated with the investigational chimeric antigen receptor (CAR) T-cell therapy JNJ-4528, which targets B-cell maturation antigen (BCMA), a protein commonly found...
Promising New Treatments for Triple-Negative Breast Cancer: Immunotherapy and Other Targeted Therapies
Clinical trials continue to demonstrate that combining immunotherapy with chemotherapy and other targeted therapies can improve survival for patients with triple-negative breast cancer, according to results presented at the 21st Annual Lynn Sage Breast Cancer Symposium in Chicago. Nearly 700...
Is Nonmetastatic Castration-Resistant Prostate Cancer a Valid Disease Category?
Does nonmetastatic castration-resistant prostate cancer really exist? Although it is considered a disease category, it turns out that the definition depends on the type of imaging used. Many patients with castration-resistant prostate cancer who were categorized as “nonmetastatic” on conventional...
RSNA 2019: MRI-Guided Ultrasound Treatment for Localized Prostate Cancer
A novel magnetic resonance imaging (MRI)-guided procedure that uses therapeutic ultrasound may effectively treat prostate cancer with minimal side effects, according to a new study presented at the 2019 annual meeting of the Radiological Society of North America (RSNA) (Abstract SSC07-07)....
Checkpoint Inhibitor Pneumonitis: A Pulmonologist’s Perspective
Oncologists have become accustomed to seeing pneumonitis associated with immune checkpoint inhibitor treatment in non–small cell lung cancer (NSCLC), requiring intervention by pulmonologists in the management of severe cases. At CHEST 2019, the annual meeting of the American College of Chest...
ASCO President-Elect Candidates Discuss Key Issues in Oncology
Patrick J. Loehrer, MD, FASCO, of the Indiana University Melvin and Bren Simon Cancer Center, and Everett E. Vokes, MD, FASCO, of the University of Chicago Medicine Comprehensive Cancer Center, were selected by the ASCO Nominating Committee as candidates for President-Elect. Below, they discuss...
Nicholas J. Petrelli, MD, Receives Tilton Award From Medical Society of Delaware
Nicholas J. Petrelli, MD, Bank of America Endowed Medical Director of ChristianaCare’s Helen F. Graham Cancer Center & Research Institute, received the Tilton Award from the Medical Society of Delaware in October. The award is named after James Tilton, MD, the first U.S. Army Surgeon General...
Using the Nobel Prize to Champion Curiosity-Driven Research in Cancer
William G. Kaelin, Jr, MD, Sidney Farber Professor of Medicine and Howard Hughes Medical Institute Investigator at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, admits that early in his research career, he and his late wife, Carolyn, would have fun...
